Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.58 |
| ▸ | ABCB1 | P08183 | 14/20 | 0.54 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.45 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4639560 | 1.00 | MEN1 (0.61) | MEN1MAPTKMT2ASTING1ABCB1 | |
| SCHEMBL4639562 | 1.00 | MEN1 (0.61) | MEN1MAPTKMT2ASTING1ABCB1 | |
| SCHEMBL4674783 | 1.00 | MEN1 (0.61) | MEN1MAPTKMT2ASTING1ABCB1 | |
| SCHEMBL4674780 | 1.00 | MEN1 (0.61) | MEN1MAPTKMT2ASTING1ABCB1 | |
| SCHEMBL24984253 | 0.95 | STING1 (0.61) | MEN1MAPTKMT2ASTING1ABCB1 | |
| SCHEMBL30141106 | 0.95 | STING1 (0.61) | MEN1MAPTKMT2ASTING1ABCB1 | |
| SCHEMBL4639449 | 0.94 | STING1 (0.59) | MEN1MAPTKMT2ASTING1ABCB1 | |
| SCHEMBL4639875 | 0.94 | STING1 (0.59) | MEN1MAPTKMT2ASTING1ABCB1 | |
| SCHEMBL4639872 | 0.94 | STING1 (0.59) | MEN1MAPTKMT2ASTING1ABCB1 | |
| SCHEMBL4639446 | 0.94 | STING1 (0.59) | MEN1MAPTKMT2ASTING1ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160068503-A1 | (-)-EPIGALLOCATECHIN GALLATE DERIVATIVES FOR INHIBITING PROTEASOME | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2016-03-10 | — | — | US | disclosed |
| US-9169230-B2 | (−)-Epigallocatechin gallate derivatives for inhibiting proteasome | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2015-10-27 | — | — | US | disclosed |
| US-20140213802-A1 | (-)-Epigallocatechin Gallate Derivatives for Inhibiting Proteasome | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2014-07-31 | — | — | US | disclosed |
| US-20120232135-A1 | (-)-Epigallocatechin Gallate Derivatives for Inhibiting Proteasome | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2012-09-13 | — | — | US | disclosed |
| US-8193377-B2 | (−)-epigallocatechin gallate derivatives for inhibiting proteasome | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2012-06-05 | — | — | US | disclosed |
| EP-1778663-A4 | (-)-EPIGALLOCATECHIN GALLATE DERIVATIVES FOR INHIBITING PROTEASOME | UNIV HONG KONG POLYTECHNIC (CN) | 2008-08-06 | — | — | EP | disclosed |
| US-20080176931-A1 | e.g. 5,7-Bis(benzyloxy)-2-[3,4,5-tris(benzyloxy)phenyl]chroman-3-yl 3-(benzyloxy)benzoate; antiproliferative, antitumor agent; reducing tumor cell growth; more potent, better bioavailability than catechin | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2008-07-24 | — | — | US | disclosed |
| EP-1778663-A1 | (-)-EPIGALLOCATECHIN GALLATE DERIVATIVES FOR INHIBITING PROTEASOME | The Hong Kong Polytechnic University (CN) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006017981-A9 | (-)-EPIGALLOCATECHIN GALLATE DERIVATIVES FOR INHIBITING PROTEASOME | UNIV HONG KONG POLYTECHNIC (CN) | 2006-05-11 | — | — | WO | disclosed |
| WO-2006017981-A1 | (-)-EPIGALLOCATECHIN GALLATE DERIVATIVES FOR INHIBITING PROTEASOME | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232135-A1 | (-)-Epigallocatechin Gallate Derivatives for Inhibiting Proteasome | PSMC1, PSME1, PSMB1 | MEN1 3560/4885MAPT 2132/4885KMT2A 2664/4885 |
| US-20160068503-A1 | (-)-EPIGALLOCATECHIN GALLATE DERIVATIVES FOR INHIBITING PROTEASOME | PSMC1, PSME1, PSMB1 | MEN1 3560/4885MAPT 2132/4885KMT2A 2664/4885 |
| US-20140213802-A1 | (-)-Epigallocatechin Gallate Derivatives for Inhibiting Proteasome | PSMC1, PSME1, PSMB1 | MEN1 3560/4885MAPT 2132/4885KMT2A 2664/4885 |
| US-20080176931-A1 | e.g. 5,7-Bis(benzyloxy)-2-[3,4,5-tris(benzyloxy)phenyl]chroman-3-yl 3-(benzyloxy)benzoate; antiproliferative, antitumor agent; reducing tumor cell growth; more potent, better bioavailability than catechin | UBE2G2, C9, BAP1 | MEN1 3996/4885MAPT 3872/4885KMT2A 3005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.